Scotiabank Reaffirms "Sector Underperform" Rating for INmune Bio (NASDAQ:INMB)

INmune Bio (NASDAQ:INMB - Get Free Report)'s stock had its "sector underperform" rating reaffirmed by analysts at Scotiabank in a research note issued to investors on Tuesday, MarketBeat Ratings reports.

INmune Bio Stock Down 7.7%

INMB stock traded down $0.18 during midday trading on Tuesday, reaching $2.13. The stock had a trading volume of 7,652,584 shares, compared to its average volume of 730,726. The firm has a market cap of $49.02 million, a price-to-earnings ratio of -1.11 and a beta of 1.55. INmune Bio has a twelve month low of $1.91 and a twelve month high of $11.64. The business has a fifty day simple moving average of $7.32 and a two-hundred day simple moving average of $7.34.

INmune Bio (NASDAQ:INMB - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.43). The firm had revenue of $0.05 million during the quarter. On average, equities analysts predict that INmune Bio will post -2.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Quarry LP acquired a new position in shares of INmune Bio during the first quarter worth about $48,000. Wells Fargo & Company MN increased its stake in shares of INmune Bio by 51.0% during the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company's stock worth $30,000 after purchasing an additional 2,155 shares during the last quarter. Beacon Pointe Advisors LLC bought a new stake in INmune Bio in the fourth quarter valued at approximately $48,000. JPMorgan Chase & Co. lifted its holdings in INmune Bio by 93.0% during the 4th quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company's stock valued at $53,000 after purchasing an additional 5,461 shares during the last quarter. Finally, Focus Partners Advisor Solutions LLC bought a new stake in shares of INmune Bio during the 1st quarter worth about $91,000. Institutional investors own 12.72% of the company's stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.